MedImmune Provides Fellowship Grants to Six Pediatric Respiratory Researchers
May 07 2007 - 11:00AM
PR Newswire (US)
- Michele Kong, M.D., University of Alabama at Birmingham, Receives
$35,000 Grant - TORONTO, May 7 /PRNewswire-FirstCall/ --
Underscoring its commitment to pediatric medicine, MedImmune, Inc.
(NASDAQ:MEDI) has divided a 2007 grant for $210,000 for pediatric
respiratory research among six pediatric fellows; each recipient's
institution will receive a $35,000 grant to support the fellow's
research. The Pediatric Fellowship Program, sponsored by MedImmune,
is designed to stimulate interest and research in the area of viral
respiratory pathogens among infectious disease fellows in the
United States. The six recipients were acknowledged on Sunday, May
6, 2007 at a reception coinciding with the annual meeting of the
Pediatric Academic Societies (PAS) in Toronto, Canada. "This
fellowship program supports and encourages research critical to the
understanding of potentially severe pediatric infectious diseases
such as respiratory syncytial virus (RSV) and influenza," said
Frank J. Malinoski, M.D., Ph.D., senior vice president, medical and
scientific affairs. An independent advisory board consisting of 15
pediatric infectious disease physicians from across the United
States selected the six fellowship recipients. All candidates were
required to be full-time fellows in an American Board of
Pediatrics-accredited fellowship program and conducting original
research as their primary focus. The 2007 Pediatric Fellowship
Program grant recipients include: -- Steven Grube, M.D. University
of Texas Southwestern Medical School Project Title: The Role of
Viral Persistence in Respiratory Syncytial Virus (RSV) - Induced
Long Term Lung Disease -- Laura Hammitt, M.D. The Children's
Hospital/University of Colorado Health Sciences Center Project
Title: Vaccine-induced Immunologic Defense Against Influenza in the
Respiratory Tree -- Michele Kong, M.D. University of Alabama at
Birmingham, AL Project Title: Matrix Metalloproteinases and
Respiratory Syncytial Virus Infection -- Jayson Luma, M.D. The
Women and Children's Hospital of Buffalo Project Title: Arachidonic
Acid Metabolites in Human Infants and Mouse Models of Respiratory
Syncytial Virus Infection -- Victoria McMeen, M.D. University of
Virginia Project Title: Viral Replication and Clearance in
Asthmatic Versus Non-Asthmatic Individuals During Experimental
Infections with Rhinovirus -- Archana Singh, M.D. Winthrop
University Hospital Project Title: Examination of the Role of
Respiratory Syncytial Virus Infection in the Pathogenesis of Lung
Disease in Cystic Fibrosis MedImmune's Pediatric Fellowship Program
is one example of the company's broader, ongoing commitment to
research and pediatric health. In another example, the Pediatric
Infectious Diseases Society (PIDS), supported by grants from
MedImmune, will present the third annual MedImmune Career
Development Award in Pediatric Infectious Disease and the second
annual Viral Respiratory Disease Fellowship tonight at a PIDS
Dinner and Awards Banquet also being held in conjunction with the
PAS annual meeting. To date, MedImmune has invested more than $2
billion in research funds to develop new and next-generation
medicines against respiratory viruses such as RSV and influenza.
About MedImmune, Inc. MedImmune strives to provide better medicines
to patients, new medical options for physicians, rewarding careers
to employees, and increased value to shareholders. Dedicated to
advancing science and medicine to help people live better lives,
the company is focused on the areas of pediatric infectious
diseases, cancer and inflammatory diseases. With more than 2,500
employees worldwide, MedImmune is headquartered in Maryland. For
more information, visit the company's website at
http://www.medimmune.com/ . Notice to Investors and Stockholders of
MedImmune This release is neither an offer to purchase nor a
solicitation of an offer to sell shares of MedImmune. MedImmune
stockholders are urged to read the relevant tender offer documents
from AstraZeneca PLC which have been filed on May 3, 2007 because
they will contain important information that stockholders should
consider before making any decision regarding tendering their
shares. AstraZeneca has filed tender offer materials with the U.S.
Securities and Exchange Commission, and MedImmune has also filed a
Solicitation/Recommendation Statement on Schedule 14D-9 with
respect to the offer. The tender offer materials (including an
Offer to Purchase, a related Letter of Transmittal and certain
other offer documents) and the Solicitation/Recommendation
Statement contain important information, which should be read
carefully before any decision is made with respect to the tender
offer. The Offer to Purchase, the related Letter of Transmittal and
certain other offer documents, as well as the
Solicitation/Recommendation Statement, are available for free at
the U.S. Securities and Exchange Commission's web site at
http://www.sec.gov/ , at AstraZeneca's website at
http://www.astrazeneca.com/ or at MedImmune's website at
http://www.medimmune.com/ . DATASOURCE: MedImmune, Inc. CONTACT:
Media, Kate Barrett of MedImmune, Inc., +1-301-398-4320 Web site:
http://www.medimmune.com/
Copyright
Medimmune (NASDAQ:MEDI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Medimmune (NASDAQ:MEDI)
Historical Stock Chart
From Aug 2023 to Aug 2024